<DOC>
	<DOC>NCT02251067</DOC>
	<brief_summary>The purpose of this study is to determine whether VPI-2690B Injection is effective in the treatment of diabetic nephropathy.</brief_summary>
	<brief_title>Phase 2 Study to Evaluate Safety &amp; Efficacy of VPI-2690B in Diabetic Nephropathy Patients</brief_title>
	<detailed_description />
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Diabetic Nephropathies</mesh_term>
	<criteria>documented diabetic nephropathy in patients with either Type 1 or Type 2 diabetics HbA1c of 7.510.5% eGFR 30110 mL/min/1.73m2 stable ACEi/ARB dose regimen stable blood pressure BMI less than or equal to 45 kg/m2 nondiabetic renal disease history of solid organ or islet cell transplant history of malignancy within previous 5 years systemic immunosuppression therapy clinically significant liver disease, hepatitis B or C or HIV monoclonal antibody treatment within previous year recent acute renal injury or major surgery significant, recent body weight change biopsy proven glomerular disease</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>